Oxigene Inc fka OXGN

[ash111]

OXGN All in one DD: P2 Study of CA4P in Recurrent Ovarian Cancer already Met Primary Endpoint of Improvement.
http://www.benzinga.com/news/16/05/8022493/oxigene-offers-results-from-phase-2-study-of-ca4p-in-recurrent-ovarian-cancer-stu?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29

At $10 cap will be around $200m.still reasonable relating market potential,imo. The FDA already granted a Fast Track status to CA4P. Very solid balance sheet,trading way under Net Assets.

OXGN to hit two birds with one stone,awesome: https://biz.yahoo.com/e/160602/oxgn8-k.html. (shareholders wouldn't have voted to no R/S if weren't pretty sure it wouldn't be necessary imo,Catalyst this month).

June 2016 Catalysts:this https://clinicaltrials.gov/ct2/show/NCT02132468

Assets/debt ratio=12 very solid(even rare),Net Assets(total assets minus total liabilities)= $22m. currently trading under $17m cap.

Many upcoming Catalysts: http://www.oxigene.com/product-
development

Latest Presentation: http://files.shareholder.com/downloads/OXGN/2196652144x0x869782/012F16F4-3081-4294-840D-9CBE0C2221D2/OXiGENE_Corporate_Roadshow_Long_Deck_-_Jan_2016_v2.pdf